A team of researchers sought to determine the incidence of inappropriate diagnosis among patients hospitalized and treated for community-acquired pneumonia.
Following a multicenter clinical trial, a new treatment for pneumonia caused by Acinetobacter baumannii-calcoaceticus has been approved for use in adults.
In a recent study, researchers examined the effectiveness of a new diagnostic tool for distinguishing between bacterial and viral community-acquired pneumonia in children.
It is a new indication for the medication, which had already been FDA-approved for the treatment of patients with complicated UTIs and complicated intraabdominal infections who have limited or no...
It is a new indication for the medication, which had already been FDA-approved for the treatment of patients with complicated UTIs and complicated intraabdominal infections who have limited or no...
Because the clinical relationship between oral candidiasis and bacterial pneumonia is unclear, researchers assessed the association among elderly patients hospitalized with systemic diseases. Here is what...
A recent noninferiority randomized clinical trial compared the safety and effectiveness of two options for the treatment of adults with community-acquired pneumonia.
The FDA has approved a new antibiotic available in both an oral and injectable form, for the treatment of community-acquired bacterial pneumonia in adults.
Previous studies have shown no benefit from antibiotic therapy that exceeds the shortest effective duration. A new study aimed to evaluate the predictors and patient outcomes associated with excess...
